BAL PHARMA LIMITED

Regd. Office: 21-22, Bommasandra Industrial Area, Anekal Taluk, Bangalore - 560 099

UNAUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31/03/2012

(Rs in Lakhs)

Statement Of Unaudited Results For The Year Ended 31/03/2012

	Particulars	3 months ended (31/03/2012)	Preceding 3 months ended (31/12/2011)	Corresponding 3 months ended (31/03/2011) the previous year	Year to date figures for current period ended (31/03/2012)	Previous year ended (31/03/2011)
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**Income from Operations**					
	(a) Net sales/income from operations (Net of excise duty)	3,976.63	3,714.14	3,795.36	13,876.31	11,429.19
	(b) Other operating income	-			230.35	-
	Total Income from Operations (net)	**3,976.63**	**3,714.14**	**3,795.36**	**14,106.65**	**11,429.19**
2	**Expenses**					
	(a) Cost of materials consumed	1,880.32	2,090.11	1,773.20	7,391.32	6,044.32
	(b) Purchases of stock-in-trade	158.88	32.79	75.98	379.93	315.74
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	311.00	(5.73)	(784.31)	113.90	(207.25)
	(d) Employee benefits expense	310.30	339.34	401.95	2,206.58	1,842.08
	(e) Depreciation and amortisation expense	138.22	73.72	86.15	357.17	346.94
	(f) Other expense	862.24	986.96	1,743.00	2,762.18	2,482.50
	Total expenses	**3,660.95**	**3,517.19**	**3,295.97**	**13,211.07**	**10,824.32**
3	**Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)**	**315.68**	**196.95**	**499.39**	**895.58**	**604.87**
4	Other income	34.75	106.27	31.55	165.87	79.42
5	**Profit / (Loss) from oridnary activities before finance costs and exceptional items (3 + 4)**	**350.43**	**303.22**	**530.95**	**1,061.45**	**684.29**
6	Finance costs	155.81	162.39	164.06	613.60	580.47
7	**Profit / (Loss) from oridnary activities after finance costs but before exceptional items (5 - 6)**	**194.62**	**140.83**	**366.89**	**447.84**	**103.82**
8	Exceptional items		-	-		-
9	**Profit /(Loss) from ordinary activities before tax (7 + 8)**	**194.62**	**140.83**	**366.89**	**447.84**	**103.82**
10	Tax Expense	31.38	10.00	15.40	76.38	63.03
11	**Net Profit / (Loss) from ordinary activities after ta (9 - 10)**	**163.24**	**130.83**	**351.49**	**371.46**	**40.79**
12	Extraordinary items (net of tax expense Rs. Lakhs)	-	-	-	-	-
13	**Net Profit / (Loss) for the period (11+12)**	**163.24**	**130.83**	**351.49**	**371.46**	**40.78**
14	Paid-up equity share capital	1,057.36	1,057.36	1,048.32	1,057.36	1,048.32
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year		-	-		2,569.20
16 i	**Earnings per share (before extraordinary items) (of Rs10/- each) (not annualised) :**					
	(a) Basic	1.54	1.24	3.35	3.51	0.39
	(b) Diluted	1.54	1.24	3.35	3.51	0.39
16ii	**Earnings per share (after extraordinary items) (of Rs10/- each) (not annualised) :**					
	(a) Basic	1.54	1.24	3.35	3.51	0.39
	(b) Diluted	1.54	1.24	3.35	3.51	0.39

Notes:

1 The above unaudited Financial Results as reviewed by the Audit Committee were approved by the Board of Directors in their meeting held on 10th May, 2012.

2 Limited Review by Statutory Auditor has been carried out and is being forwarded to Stock Exchanges.

3 Previous year figures are regrouped, wherever necessary;

4 The Company has only one segment of activity namely, 'Pharmaceuticals';

5 Investor Complaints for the quarter ended 31st March, 2012 - Opening - Nil, Received - 04, Resolved - 03, Closing - 01.

Bangalore

10th May, 2012

BAL PHARMA LIMITED * 52 * BANGALORE

By order of the Board of Directors

For Bal Pharma limited

Shailesh Siroya

Managing Director